Genomics England and Lantern Pharma that emphasizes on precision oncology incorporating Artificial intelligence asserted that Lantern will associate with Genomics England’s Discovery Forum Industry Partnership.
The partnership aims to revolutionize extensive research into breakthrough treatment options thereby benefiting patients. Lantern Pharma is reinventing the cancer drug development process, tailoring multiple promising precision drug programs to the right cancer patients through use of their RADR platform (ResponseAlgorithm for Drug Rescue and Positioning). Right patient stratification is still considered by many in pharma as the holy grail. Lantern is disrupting this using seamless integration of relevant existing data, generation of new clean data closely modeling real world evidence and very focused artificial intelligence technology application to further model this data and distill into meaningful information that can identify & stratify right patients with high accuracy.
Genomics project is set to be the largest of its kind in the world, and aims to sequence 100,000 genomes from around 70,000 people with rare disease and cancer. Combining this with their health data will enable more diagnoses and improved personalized treatments for patients in the future. The Genomics England Discovery Forum provides an engagement platform for industry partners, academia, the NHS, and the wider genomics community.
Arun Asaithambi, Lantern Pharma CEO, said: “We are delighted to have been invited to participate in the Discovery Forum and look forward to working with Genomics England, other Forum members and the wider UK life science ecosystem to advance developments in precision oncology.”